Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer
Molecular imaging with ⁶⁸Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer. If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites. If you want to…